Larson Financial Group’s Corcept Therapeutics CORT Stock Holding History

Larson Financial Group’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.3K	Buy	84 +9	+12%	+$543	﹤0.01%	2589
2026 Q1	$3.02K	Buy	75 +8	+12%	+$299	﹤0.01%	2828
2025 Q4	$2.33K	Sell	67 -394	-85%	-$30.9K	﹤0.01%	2731
2025 Q3	$38.3K	Buy	461 +442	+2,326%	+$32K	﹤0.01%	1277
2025 Q2	$1.4K	Buy	19 +4	+27%	+$290	﹤0.01%	2536
2025 Q1	$1.71K	Buy	15 +3	+25%	+$183	﹤0.01%	2217
2024 Q4	$605	Buy	12 +4	+50%	+$210	﹤0.01%	2152
2024 Q3	$370	Hold	8	–	–	﹤0.01%	2208
2024 Q2	$260	Buy	+8	New	+$219	﹤0.01%	1999

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Larson Financial Group's CORT Position: Q2 2026 in Review

Larson Financial Group increased its Corcept Therapeutics (CORT) stake by 12% in Q2 2026, buying an estimated $543 and bringing the position to 84 shares worth $7.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2589.

Larson Financial Group first reported a position in CORT in Q2 2024 and has held it in 9 quarters since. The position peaked at $38.3K in Q3 2025. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

Larson Financial Group held 84 shares of Corcept Therapeutics worth $7.3K as of Q2 2026.
Larson Financial Group bought 9 Corcept Therapeutics shares in Q2 2026, an estimated $543.
Corcept Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #2589 holding.
Larson Financial Group first reported a position in Corcept Therapeutics in Q2 2024 and has held it in 9 quarters since.
Larson Financial Group's Corcept Therapeutics position peaked at $38.3K in Q3 2025.
423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.